Vascular Biogenics (STU:0VB) EBIT: €-15.55 Mil (TTM As of Jun. 2023)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

What is Vascular Biogenics EBIT?

Vascular Biogenics STU:0VB 10 EBIT is €-15.55 Mil as of Jun. 2023. GuruFocus rates STU:0VB with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

Vascular Biogenics's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was €-0.80 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was €-15.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vascular Biogenics's annualized ROC % for the quarter that ended in Jun. 2023 was -93.64%. Vascular Biogenics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -851.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vascular Biogenics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -18.67%.

Vascular Biogenics (STU:0VB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vascular Biogenics's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-1.208 * ( 1 - 0% )	/	( (1.067	+	1.513)	/ 2 )
=	-1.208	/	1.29
=	-93.64 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	26.258	-	7.243	-	( 24.372	-	max(0, 7.243	-	25.191	+	24.372	))
=	1.067

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22.748	-	3.47	-	( 22.396	-	max(0, 4.893	-	22.658	+	22.396	))
=	1.513

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Vascular Biogenics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.188	/	( ( (0.749 + max(-6.424, 0))	+	(0 + max(-4.631, 0)) )	/	2 )
=	-3.188	/	( ( 0.749	+	0 )	/	2 )
=	-3.188	/	0.3745
=	-851.27 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.819)	-	(7.243	+	0	+	0)
=	-6.424

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.262)	-	(3.47	+	0	+	1.423)
=	-4.631

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vascular Biogenics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-15.545	/	83.246
	=	-18.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vascular Biogenics EBIT Related Terms

Vascular Biogenics EBIT Historical Data

* Premium members only.

The historical data trend for Vascular Biogenics's EBIT can be seen below:

Vascular Biogenics EBIT Chart

Vascular Biogenics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-17.88

-17.29

-19.83

-26.44

-30.42

Vascular Biogenics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT	Get a 7-Day Free Trial															-8.90	-9.23	-3.08	-2.45	-0.80

STU:0VB vs MBIO, GNPX, LEXX: EBIT Comparison

For the Biotechnology subindustry, Vascular Biogenics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vascular Biogenics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's EV-to-EBIT falls into.

Save Embed

Vascular Biogenics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.55 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-15.55 Mil mean?

Vascular Biogenics (STU:0VB) has a EBIT of €-15.55 Mil as of Jun. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vascular Biogenics.

Is Vascular Biogenics' EBIT too high?

Vascular Biogenics' current EBIT is €-15.55 Mil. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Vascular Biogenics' EBIT compare to MBIO and GNPX?

Vascular Biogenics' EBIT of €-15.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vascular Biogenics. Vascular Biogenics's current EBIT is €-15.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vascular Biogenics stock overvalued right now?

Vascular Biogenics (STU:0VB) has a current EBIT of €-15.55 Mil. The current EBIT is €-15.55 Mil. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current EBIT is €-15.55 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vascular Biogenics Business Description

Industry Healthcare Biotechnology

Comparable Companies MBIO GNPX LEXX OTLC SRZN LABP TNXP SNTI LPCN ALZN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 8 HaSatat Street, Modi’in, ISR, 7178106

Website https://www.vblrx.com

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.